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Rab27a is required for polarized secretion of lysosomes
from cytotoxic T lymphocytes (CTLs) at the immuno-
logical synapse. A series of Rab27a-interacting proteins
have been identified; however, only Munc13-4 has been
found to be expressed in CTL. In this study, we screened
for expression of the synaptotagmin-like proteins (Slps):
Slp1/JFC1, Slp2-a/exophilin4, Slp3-a, Slp4/granuphilin,
Slp5 and rabphilin in CTL. We found that both Slp1 and
Slp2-a are expressed in CTL. Isoforms of Slp2-a in CTL
showed variation of the linker region but conserved the
C2A and C2B and Slp homology (SHD) domains. Both
Slp1 and Slp2-a interact with Rab27a in CTL, and Slp2-a,
but not Slp1, is rapidly degraded when Rab27a is absent.
Slp2-a contains PEST-like sequences within its linker
region, which render it susceptible to degradation. Both
Slp1 and Slp2-a localize predominantly to the plasma
membrane of both human and mouse CTLs, and we show
that Slp2-a can focus tightly at the immunological syn-
apse formed with a target cell. Individual knockouts of
either Slp2-a or Slp1 fail to impair CTL-mediated killing of
targets; however, overexpression of a dominant-negative
construct consisting of the SHD of Slp2-a, which is 56%
identical to that of Slp1, reduces target cell death,
suggesting that both Slp1 and Slp2-a contribute to
secretory lysosome exocytosis from CTL. These results
suggest that both Slp1 and Slp2-a may form part of
a docking complex, capturing secretory lysosomes at
the immunological synapse.
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Cytotoxic T lymphocyte (CTL) cells use polarized secretion
of lysosomal organelles to destroy virally infected and
tumorigenic cells. Secretion occurs at a precise point
within the immunological synapse formed between CTL
and target cell (1). The mechanism of secretion is unusual:
recognition of the target by the T-cell receptor triggers
centrosomal polarization to a precise location within the
immunological synapse, next to the central supramolecular
activation complex (2,3). Secretory lysosomes move along
the microtubules in the minus direction towards the
microtubule-organizing centre (MTOC) and are delivered
as the centrosome ‘docks’ at the membrane.
Both Rab27a and its binding partner Munc13-4 are essen-
tial for lysosomal secretion from CTL, and loss of either
Rab27a (4,5) or Munc13-4 (6) leads to loss of secretion,
with the granules polarized towards the immunological
synapse but unable to undergo secretion. Rab27a also
plays a key role in secretory lysosome secretion in
a number of cell types with secretory lysosomes or related
organelles including melanocytes (7,8), neutrophils (9) and
pancreatic beta cells (10). In each of these cell types,
Rab27a mediates secretion by interacting with different
effector proteins: in melanocytes, Rab27a mediates trans-
fer of lysosome-related melanosomes from the plus ends
of microtubules to the actin cytoskeleton by interactions
with Slac2-a/melanophilin and myosin Va (reviewed in 11).
Rab27a also mediates anchoring of melanosomes to the
plasma membrane through interaction with synaptotagmin-
like protein (Slp)2-a (12). In neutrophils, Rab27a inter-
acts with Slp1/JFC1 (9), and in pancreatic alpha and beta
cells, Rab27a interacts with Slp2-a/exophilin4 (13) and
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446 www.traffic.dkSlp4/granuphilin (14), respectively. These interactions are
thought to promote the targeting of the granules towards
the plasma membrane, possibly by mediating docking.
A family of six different Rab27a-binding Slps have been
identified, all of which contain an N-terminal Slp homology
domain (SHD), which binds Rab27a in a GTP-dependent
manner, a central linker region and two C2 domains
capable of binding to phospholipid membranes (15). In this
paper, we ask whether Slp proteins are expressed in CTL.
We find expression of Slp1 and Slp2-a, both of which bind
to Rab27ain CTL. Slp2-a is readily degraded because of the
presence of PEST-like sequences, and in the absence of
Rab27a, Slp2-a protein levels are also reduced. Slp2-a
associates with the plasma membrane and focuses at
the immunological synapse formed between CTL and
target. Expression of dominant-negative Slp2-a, lacking
the C2 domains, reduces CTL-mediated killing. These
results suggest that Slp2-a may form part of the docking
complex,whichtethers secretorylysosomestotheplasma
membrane as they reach the immunological synapse.
Results
Slp1 and novel isoforms of Slp2-a are
expressed in CTL
Cell lysates from human and mouse CTLs were screened
for expression of Slps by Western blotting (Figure 1).
Antibodies against Slp1 SHD revealed bands in both
human and mouse CTLs lysates. In human CTL lysates,
a dominant band with an apparent molecular weight of
58 kDa was present, and in mouse, two bands of apparent
molecular weights of 60 and 62 kDa were seen (Figure 1
A). Because no alternative splice form of Slp1 has been
reported and complementary DNA (cDNA) cloning from
CTL produced only the reported isoform, it is possible
that the upper bands may correspond to either a post-
translationally modified form of Slp1 or a cross-reactive
protein. A faint upper band and the lower band marked
with an asterisk are non-specific. Antibodies against either
Slp2-aSHD(Figure 1A)orlinkerregion(notshown)revealed
single strong bands of 97 kDa in human and 100 kDa in
mouse CTL lysates.
We have previously reported three different isoforms of
Slp2-a generated from differential splicing, which have
different expression patterns in different mouse tissues
(16). In order to determine which splice forms of Slp2-a are
expressed in mouse CTL, we cloned and sequenced
cDNAs corresponding to Slp2-a from mouse CTL. We
found two splice forms of Slp2-a in CTL derived from
C57BL/6 mice. The first form is the previously described
2S-II isoform (accession number: AB057761), which lacks
16 amino acids (539–554) from the linker region of Slp2-a.
The second form, which combines the deletions seen in
the 2S-II and 2S-III isoforms previously described (acces-
sion numbers: AB057761 and AB057762), lacks both the
2S-II site (amino acids 539–554) and the 2S-III site (amino
acids 587–626) from the linker region of Slp2-a. Except for
Figure 4, all subsequent experiments in this study were
carried out with the latter splice variant, the sequence of
which is given in Figure S1. The SHD and C2 domains are
conserved in both variants.
Slp1 and Slp2-a bind to Rab27a in CTL lysates
Both Slp1 and Slp2-a have been shown to bind to Rab27a,
a protein that is required for CTL secretion. In order to
Figure 1: Expression of Slp1 and Slp2-a in CTL. A) Western
blots showing mouse and human CTL lysates probed for expres-
sion of Slp1-5 and rabphilin (Rph). Lanes show control lysates of
T7-tagged Slp1-5 or Rph (lane 1) and lysates from human (lane 2)
and mouse CTLs (lane 3). Blots are probed with antibodies against
Slp1-5 and Rph as described in Imai et al. (37). The marker on the
left shows the relative migration of the 97.4 kDa molecular weight
marker. A longer exposure of Slp1 is shown on the right. Note that
the Slp1 and Slp2-a proteins, but not the other Slp proteins, were
detected in human and mouse CTLs (indicated by arrows).
Asterisk corresponds to non-specific bands. B) Recombinant T7-
tagged Slp1-5 and Rph were used as positive controls in A. Similar
amounts of the T7-tagged proteins from COS-7 cell lysates were
loaded into each lane and probed with anti-T7 tag antibody as
described previously (37). Relative migration of molecular weight
markers (in kiloDalton) is shown on the left.
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Slp2-a Focuses at the Immunological Synapsedemonstrate that Slp1 and Slp2-a were able to interact
with Rab27a, mouse CTL lysates were precipitated with
antibodies against Slp1, Slp2-a and the related protein,
Slac2-c, which is not expressed in CTL. Western blots
were then probed with antibodies against Rab27a and the
Slp1, Slp2-a or Slac2-c (Figure 2). Immunoprecipitation
with Slp1 and Slp2-a both co-precipitated Rab27a, demon-
strating that Rab27a is able to interact with Slp1 and Slp2-a
in CTL (lanes 2 and 4 in the top panel). By contrast, Slac2-c
could not be precipitated from CTL lysates (lane 6 in the top
and bottom panels).
Cell lysates from ashen mice that lack Rab27a show
decreased levels of Slp2-a, which can be observed both
in fresh lysates and more noticeably in lysates that have
been frozen and thawed (Figure 3A). Actin controls show
equal levels for CTL lysates derived from ash/ash or ash/þ
mice regardless of whether lysates were prepared freshly
or whether they had been frozen and thawed. Rab27a is
also present at equivalent levels in both fresh and freeze-
thawed lysates from ash/þ CTL. Slp2-a appears to be
highly susceptible to degradation, with the band of approxi-
mately 100 kDa molecular weight strongest in the ash/þ
fresh (lane 1) compared with freeze-thawed lysate (lane 4)
in which a degradation product of 36 kDa is seen. Slp2-a
levels are also affected by the presence of Rab27a as both
fresh and frozen lysates show increased levels of Slp2-a in
ash/þ lysates compared with ash/ash lysates. This is
particularly noticeable once samples have been frozen
(lanes 3 and 4).
Similar results are seen in cell lysates from human CTL
lacking Rab27a (Figure 3B). CTL lysates derived from
healthy (lane 1), Munc13-4-deficient (lane 2) and Rab27a-
deficient (lane 3) cells were probed with antibodies to
Slp1, Slp2-a and actin. Munc13-4 and Rab27a mutations
were confirmed by genomic sequencing, and both cDNA
and genomic sequencing were used to confirm that
there were no mutations present in Slp2-a in the Rab27a-
deficient patient. While actin levels are comparable
between lanes 1–3, the signal for Slp2-a is markedly
decreased in the cell lysate lacking Rab27a. Protein levels
for Slp1 do not decrease in the lysate from cells lacking
Rab27a.
These results suggest that Slp2-a is highly susceptible to
degradation and that it is stabilized by interaction with
Rab27a. Similar stabilization of Slac2-a/melanophilin,
another Rab27a effector in melanocytes, by interaction
with Rab27a has been reported in ashen melanocytes (17).
Interestingly, Slac2-a/melanophilin has recently been
shown to be readily degraded by several proteases,
including endogenous calpains in melanocytes (18),
because it contains potential PEST sequences, which
were originally identified (19,20) as motifs that target
proteins for increased susceptibility for degradation (21).
We therefore attempted to investigate whether Slp2-a also
contains PEST-like sequences and inspected its primary
sequences.
Slp2-a contains PEST-like sequences and is readily
degraded
Four separate domains have been identified in Slp2-a
(Figure 4A): the SHD, which binds Rab27a, the linker
region and the phospholipid-binding C2A and C2B do-
mains. Each of these domains was examined for the
presence of PEST-like sequences [containing the amino
acids proline (P), glutamic acid (E), serine (S) and threonine
(T)]. A bioinformatic search of the SHD, linker and C2
domains of murine Slp2-a identified 14 different PEST-like
clusters, with 1 in the SHD, 11in the linker and 2 in the C2B
domain. In order to test whether Slp2-a showed increased
susceptibility to degradation, T7-tagged Slp1-5 proteins
were expressed in COS-7 cells and cell lysates were
prepared in the absence of protease inhibitors and incu-
bated at 258C for 30 min with or without 100 ng/mL of
trypsin before immunoblotting and probing with antibodies
against T7 tag (Figure 4B). Slp1 and Slp3-a showed no
decrease in the intensity of the protein band in the
presence of trypsin, while Slp4-a and Slp5 showed a mod-
est reduction. By comparison, Slp2-a showed a dramatic
reduction in the amount of protein detected after trypsin
treatment in vitro.
Figure 2: Slp1 and Slp2-a interact with Rab27a from CTL
lysates. Western blots of mouse CTL total lysates (lanes 1, 3
and 5) or immunoprecipitatedwith antibodies againstSlp1 (lane 2),
Slp2-a (lane 4) or Slac2-c (lane 6), probed with anti-Rab27a or anti-
Slp/Slac2 antibody. Immunoprecipitation with anti-Slp1, anti-Slp2-a
or control anti-Slac2-c IgG was performed as described in the
Materials and Methods. Coimmunoprecipitated Rab27a was de-
tected by immunoblotting with anti-Rab27a antibody (indicated by
arrowheads; lanes 2, 4 and 6 in the top panel). Immunoprecipitated
Slp1, Slp2-a and Slac2-c were then visualized by immunoblotting
with specific antibodies (indicated by arrowheads; lanes 2, 4 and 6
in the bottom panel). Non-specific bands of IgG used for immuno-
precipitation are indicated by IgG. Note that both anti-Slp1 and anti-
Slp2-a IgGs, but not Slac2-c IgG, immunoprecipitated Rab27a
(lanes 2 and 4 in the top panel). Under our experimental conditions,
anti-Slp1 IgG immunoprecipitated Slp1 protein (and also Rab27a
protein) more efficiently than anti-Slp2-a IgG did Slp2-a protein.
Relative migration of molecular weight markers (in kiloDalton) is
shown on the left. IP, immunoprecipitate.
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endogenous calpains in a calcium-dependent manner, total
cell lysates of melanocytes were prepared in the absence
of protease inhibitors. Cell lysates were incubated at 308C
for 1 h with either 2 mM EGTA or 750 mM Ca
2þ in the
presence or absence of calpain inhibitors and probed with
anti-Slp2-a antibody. Slp2-a is readily degraded compared
with the actin controls only in the presence of calcium.
Both calpastatin peptide and calpain inhibitor III are able to
prevent the calcium-mediated degradation (Figure 4C).
These results demonstrate that Slp2-a might be degraded
endogenously in response to calcium-dependent calpains,
suggesting that rapid degradation may provide a way for
regulating Slp2-a activity.
Slp1 andSlp2-a arelocalized on the plasmamembrane
and can focus at the immunological synapse
Antibodies raised against Slp1 and Slp2-a are unable to
detect endogenous protein in CTL by immunofluores-
cence. We therefore tagged Slp1 and Slp2-a at N- or
C-termini with either enhanced green fluorescent protein
(EGFP) or maxFP Green (pmaxGFP) and expressed these
constructs in human and mouse CTLs (Figure 5). Slp1 and
Slp2-a tagged with EGFP at the amino terminal end of the
protein (Figure 5A) were expressed in activated human T
cells (Figure 6), and both Slp1 (Figure 6A) and Slp2-a (Fig-
ure 6B) showed strong association with the plasma mem-
brane. There was no obvious overlap with the granule
stainings shown by granzyme A (red, A) or cathepsin D
(blue, B). This suggests that the dominant localization of
both Slp1 and Slp2-a is at the plasma membrane. This
differs markedly from the localization of Rab27a in CTL,
which localizes to the lytic granules (22). Figure 6C and
Movie S1 show two CTLs derived from a transgenic
mouse expressing Rab27a–green fluorescent protein
(GFP) under the control of the Rab27a promoter (22).
One CTL is conjugated to a P815 target cell, and both are
loaded with Lysotracker Red to mark the lysosomes.
Some cytosolicRab27a is visible,but the majority is closely
associated with the lytic granules, both near the immuno-
logical synapse and at the rear of the CTL as well as in the
unconjugated CTL in the bottom right of the Movie S1.
Because the initial constructs were both tagged at the
amino terminus, next to the SHD where Rab27a binds, we
asked whether the localization might differ if tagged at the
C-terminus (Figure 5C). We therefore expressed Slp2-a
tagged at the N- and C-termini in the rat basophilic cell
line, RBL, as this cell line is easily transfectable and
possesses secretory lysosomes to which both Rab27a
and Munc13-4 will localize correctly (23). Both Slp2-a
tagged at the N- (Figure 7, panels A–C) and C-termini
(Figure 7, panels D–F) gave a predominant localization to
the plasma membrane; however, in some cells, granule
localization could be seen when Slp2-a was tagged at the
C-terminus (Figure 7, panels G–I), as Slp2–a GFP colocal-
ized with anti-Lgp100 staining (I). We confirmed the
specificity of our anti-Slp2-a SHD-purified rabbit antibody
Figure 3: Slp2-a is readily degraded and sta-
bilizedbyassociation withRab27a.A)Western
blots of mouse CTL lysates from heterozygous or
homozygous ashen mice prepared and run on
SDS–PAGE immediately (fresh lysate) or stored
for 6 weeks at  208C before analysis. The nitro-
cellulose filter was probed with anti-Slp2-a anti-
body, washed and reprobed with anti-Rab27a and
anti-actin antibodies. WT, wild type. B) Western
blots of human CTL lysates derived from healthy
donors (lane 1) and patients lacking Munc13-4
(lane 2) or Rab27a (lane 3) probed with antibodies
to Slp1 SHD, Slp2-a SHD or actin. Relative
migration of molecular weight markers (in kilo-
Dalton) is shown on the left.
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(B, E and H).
We then asked whether Slp localization changed upon
formation of the immunological synapse by expressing
Slp1 and Slp2-a in mouse CTL and examining localization
in single and conjugated cells. Expression of Slp1 was not
detectable, but Slp2-a tagged at the N-terminus could
be detected by pmaxGFP expression (J–L) and enhanced
by staining with the anti-Slp2-a SHD antibody (M–O).
Figure 5: Scheme of constructs used in this study. Schematic diagram showing the domains of Slp1 or Slp2-a with the SHD at the
amino terminus and two C2 domains at the carboxy terminus (A). Constructs tagging either N-terminus (B) or C-terminus (C) were used in
this study as was a dominant-negative construct using just the SHD fused to maxFP Green (pmaxGFP) (D). A glutathione S-transferase
fusion protein of the SHD (E) was used to produce antibodies.
Figure 4: Slp2-a is readily degraded by proteases and endogenous calpains. A) Scheme to show the PEST sequence distribution in
the 950 amino acid Slp2-a sequence encoded by full-length mouse Slp2-a (accession number: AB057754), indicating the SHD that binds
Rab27a (15), C2A that binds phosphatidylserine (PS) (12) and C2B domains. The sites where splicing variation within the linker have been
reported are shown, 2S-I, 2S-II and 2S-III, as well as the content of four amino acids (Pro, Glu, Ser and Thr) in each domain and the number
of clusters of PEST-like sequences identified by eye. B) COS-7 cell lysates expressing T7-tagged Slp1-5 treated with (þ) or without ( )
100 ng/mL trypsinand probedwith anti-T7antibody.C) Cell lysatesfrom melanocytes expressingSlp2-atreatedwith calpastatinpeptideor
calpain inhibitor in the presence of calcium (þ) and probed with anti-Slp2-a or anti-actin antibody. Relative migration of molecular weight
markers (in kiloDalton) is shown on the left.
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the plasma membrane and did not colocalize with lyso-
somes (Figure 7, panel K). In conjugated CTL, Slp2-
a focuses at the immunological synapse (L and O).
Single knockouts of Slp1 and Slp2-a do not interfere
with killing, but a dominant-negative Slp2-a SHD
reduces CTL-mediated killing of target cells
In order to ask whether Slp1 and Slp2-a might play a role in
killing, we examined the ability of CTL generated from Slp1
 /  and Slp2-a  /  mice (24) to kill targets. The absence
of protein from CTL generated from Slp2-a  /  mice was
confirmed by Western blotting using an antibody against
Slp2-a SHD while actin levels were equivalent (Figure 8A).
CTL generated from both Slp2-a þ/  and  /  mice killed
targets well with no significant reduction of killing from
that of the Slp2a-deficient CTL (Figure 8B), suggesting that
if Slp2-a is involved in killing, there may be functional
redundancy with other protein(s) such as Slp1. We there-
fore examined the ability of CTL from recently generated
Slp1-deficient mice (C. Saegusa, S. Itohara and M. Fukuda,
manuscript in preparation) in which insertion of neomycin
was used to replace exon 1 of Slp1. Western blotting of
CTL lysates with anti-Slp1 SHD antibody produced three
bands of 58, 60 and 62 kDa of which the 60 kDa was
specificallymissing inCTL from Slp1  / mice (Figure 8C),
suggesting that this band corresponds to the single iso-
form of Slp1 detected by cDNA cloning. Actin levels were
equivalent in Slp1  /  and þ/  lysates. CTL from Slp1  / 
and Slp1 þ/  mice showed similar levels of killing (Fig-
ure 8D), suggesting that loss of Slp1 alone was insufficient
to disrupt killing.
We therefore generated a dominant-negative construct
consisting of the SHD of Slp2-a fused to GFP. Because the
SHDs of Slp1 and Slp2-a are 56% identical and 73% similar
in amino acid sequence, we reasoned that overexpression
of the dominant-negative construct might interfere with
Rab27a binding of both endogenous Slp1 and Slp2-a. CTLs
were transfected with dominant-negative SHD–GFP, and
transfected cells were sorted for GFP expression before
assaying killing of P815 target cells. Target cell killing was
reduced, although not ablated (Figure 9), suggesting that
Slp1 and Slp2-a together play a positive regulatory role in
CTL killing.
Discussion
Rab27a has been shown to play a key role in secretion
from both CTL and melanocytes. Loss of Rab27a prevents
secretion from both melanocytes and CTL leading to
Griscelli syndrome with albinism and immunodeficiency
(4). In melanocytes, the series of protein interactions
leading to melanosome secretion is well understood, with
Rab27a on the melanosomes interacting with Slac2-a/
melanophilin that in turn enables a tripartite complex to
form with myosin Va, which can transfer the melano-
somes from the microtubule to the actin cytoskeleton
(reviewed in 11). Rab27a, Slac2-a/melanophilin and myosin
Va are all required for melanosome secretion, but neither
Slac2-a/melanophilin nor myosin Va is required for secre-
tion from CTL.
Not only do the proteins involved in mediating secretion
differ between CTL and melanocytes but also the mechan-
ics of secretion differ. Melanosomes move from a pericen-
triolar localization towards the periphery in a plus-end
direction on microtubules, where they are captured onto
the cortical actin cytoskeleton by myosin Va (11). Secretion
from CTL is almost the reverse of this, with the centro-
some of the MTOC moving to the point of secretion at the
immunological synapse and the lytic granules moving in
a minus-end direction towards the MTOC and the site of
secretion (2). The actin cytoskeleton is cleared away from
the point of secretion, and the granules appear to be
delivered to the plasma membrane directly from micro-
tubules. Although Rab27a is required for both melano-
some and lytic granule secretion, it has become clear that
Rab27a is interacting with different effector proteins in
order to accomplish this.
Figure 6: Slp1 and Slp2-a localize to the plasma membrane in CTL. Activated human CD3 cells were transfected with A) human Slp1–
EGFP and co-stained with granzyme A (red) and B) human Slp2-a–EGFP and co-stained with cathepsin D (blue). C) CTL derived from
transgenic mice expressing Rab27a–EGFP and co-labelled with Lysotracker Red to show lysosomes recognize P815 targets (unlabelled).
Scale bars: 10 mm.
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mouse and man (25,26). Ten of these are Slps (Slp1/JFC1,
Slp2-a/exophilin4, Slp3-a, Slp4/granuphilin, Slp5, rabphilin,
Slac2-a/melanophilin, Slac2-b, Slac2-c/MyRIP and Noc2)
containing SHD-Rab27a-binding domains. The eleventh is
Munc13-4, which contains a novel Rab27a-binding domain
distinct from the SHD (23,27). Munc13-4 is required for
granule exocytosis from CTL, and granules in CTL deficient
in Munc13-4 are found docked, but unable to fuse, at the
plasma membrane in the immunological synapse (6,28).
Munc13-4 is thought to act as a priming protein for
SNAREs by analogy to the neuronal protein Munc13-1,
which is thought to hold t-SNAREs in an open conforma-
tion and act as a priming factor for membrane fusion
(29,30), although the details of its role are yet to be fully
defined (reviewed in 31).
Figure 7: Slp2-a localizes predom-
inantly to the plasma membrane
and focuses at the immunological
synapse. Mouse Slp2-a tagged with
pmaxGFP at either the amino terminus
(panels A–C) or the carboxy terminus
(panels D–I) expressed in RBL cells
(panels A–I). Panels A, D and G show GFP
fluorescence, and B and E show staining
with anti-Slp2-a SHD antibody. Panel H
showsLgp100staining.PanelsC,F and I
are merged images of A and B, D and E,
and G and H, respectively. Panels J–O
show N-terminally pmaxGFP-tagged
mouse Slp2-a expressed in mouse CTL
either unstained (panels J and L) or
counterstained with anti-Lamp2 anti-
body ABL-93 (panel K) or anti-Slp2-a
SHD antibody (panels M–O). Letter T
indicates P815 target cell. All panels to
the same scale. Scale bar: 10 mm.
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granules, and it is not clear how the granules are passed
to the plasma membrane prior to docking and secretion.
Slp4/granuphilin has been shown to be involved in docking
insulin granules to the fusion machinery at the plasma
membrane, and mice deficient in Slp4/granuphilin show
fewer granules docked at the plasma membrane even
though exocytosis is enhanced (14), suggesting that Slp4/
granuphilin plays a negative regulatory role in exocytosis
(14,32).
In the present study, we have examined the expression of
Slp proteins in CTL and find expression of Slp1 and Slp2-a
in both mouse and human CTLs. The same expression
pattern is found in human natural killer cells (data not
shown). Cloning cDNAs from CTL, we found that the
different splice forms generated from the 19 exons
conserved the SHD and C2 domains but showed a novel
pattern of deletion within the linker region, the function of
which remains unknown. We found a similar picture in
cDNA cloned from human CTL where we identified
multiple splice variants within the region encoding the
linker region, but in each case, the SHD and C2 domains
were present. Only a single isoform of Slp1 has been
identified (33), and cDNA cloning from both mouse and
human CTLs identified only this isoform. Our Western
blots using the anti-Slp1 SHD antibody showed only
a single clear band reproducibly detected from human
CTL lysates (Figures 1 and 3B) but three bands from
Figure 8: Slp2-a and Slp1-deficient CTL
show normal levels of killing. A) Western
blots of CTL lysates probed with anti-Slp2-a
SHDoractinantibodiesandB)killingassays
from Slp2-a /  (triangles)and þ/  (circles)
mice. C) Western blots probed with anti-
Slp1 SHD or actin antibodies and D) killing
assays showing percentage target cell
lysis from Slp1 þ/  (circles) and Slp1  / 
(triangles). Error bars represent standard
deviation from triplicates for each CTL:
target ratio. Molecular weight markers
shown on the left of Western blots (in
kiloDalton) with arrows pointing to the
bands corresponding to Slp2-a and Slp1.
Figure 9: Expression of a dominant-negative SHD from Slp2-a
reduces CTL-mediated killing. Killing assay showing percent-
age lysis of targets at differing ratios of effector CTL to target in
CTL expressing pmaxGFP (bold line) or the dominant-negative
construct (broken line) expressing the SHD of Slp2-a tagged with
pmaxGFP. Error bars show standard deviation from triplicates.
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only one isoform detected at the cDNA level and only the
60-kDa band disappears in CTL derived from an Slp1-null
mouse, it seems most likely that only the 60-kDa band
represents murine Slp1. We do not know what the 58 and
62 kDa cross-reactive bands represent.
Both Slp1 and Slp2-a bind Rab27a in CTL. However, in CTL
derived from mice lacking Rab27a, we noted that Slp2-a,
but not Slp1, was less stable (Figure 3). This loss of
stability of Slp2-a, but not Slp1, in the absence of Rab27a
most likely arises from the presence of multiple PEST-like
sequences, which render it readily degraded (Figure 4).
SimilarPEST-likesequenceshave been identifiedinSlac2-a/
melanophilin (18). Studies in melanocytes suggested
that this overexpression might have a functional role as
overexpression of a mutant form of Slac2-a/melanophilin
lacking the PEST-like sequences resulted in the increased
rate of perinuclear aggregation of melanosomes. This sug-
gested that endogenous degradationof Slac2-a/melanophilin
may be important for releasing the melanosomes from the
microtubule cytoskeleton to the actin cytoskeleton. These
results suggest that Slp2-a is stabilized by its interaction
with Rab27a and that this may have functional consequen-
ces in vivo.
Expression of Slp1 and Slp2-a in CTL showed that both
localized predominantly to the plasma membrane (Fig-
ure 7). Because these experiments were carried out with
Slp2-a tagged at the N-terminus that might interfere with
membrane association by the Rab27a-binding SHD, we
tagged Slp2-a at both N- and C-termini to investigate
membrane localization in RBL cells, which also express
Rab27a (34). Using a C-terminally tagged Slp2-a, the pre-
dominant membrane association remained at the plasma
membrane, although a rare cell could be found with
lysosomal-associated Slp2-a. In CTL, endogenous Slp2-a
could not be detected by immunofluorescent labelling.
This is consistent with previous studies that have shown
that neither endogenous Rab27a nor Munc13-4 can be
detectedinCTL(22,35)andpresumablyreflectsarelatively
low level of expression of these proteins in CTL. We
therefore expressed both Slp1 and Slp2-a fused to
pmaxGFP in CTL and found that both localized to the
plasma membrane. Slp2-a–GFP localized to the plasma
membrane of CTL whether tagged at the N- or C-terminus,
although the N-terminally tagged construct was expressed
more efficiently in all cell lines tested. This might reflect
membrane localization by the C2A and C2B domains,
which may be hindered when pmaxGFP is fused to the
carboxy terminus of the protein close to the C2 domains.
Strikingly, Slp2-a focussed at the point of contact between
CTL and target, within the immunological synapse, sug-
gesting that this protein might play an important role in
granule exocytosis from CTL. It is possible that Slp1 also
focuses at the immune synapse, but expression of this
construct in mouse CTL was inefficient, and we were
unable to see transfected conjugates.
How might Slp2-a function? The membrane localization we
observed in CTL for Slp1 and Slp2-a and the clustering of
Slp2-a in the immunological synapse suggest that Slp1 and
Slp2-a may act as part of a docking complex which, by
interaction with Rab27a on the lytic granules, might serve
to capture the granules as they reach the plasma mem-
brane and dock them prior to secretion. Slp2-a is involved
in mucus secretion by gastric surface mucous cells
because a deficiency of granule docking and reduction of
mucus secretion were observed in Slp2-a  /  mice (24).
In addition, Slp2-a is thought to target glucagon granules to
the plasma membrane in pancreatic alpha cells because
overexpression of Slp2-a containing mutations that pre-
vent C2A binding to phospholipid membranes inhibits
evoked glucagon secretion from aTC1.6 cells (13). More
recently, the C2 domains of synaptotagmins have been
found to be important for producing membrane curvature
and have been proposed to provide a general mechanism
for promoting SNARE fusion (36). Virtually, all C2 domains
from synaptotagmins tested induced membrane curvature
in a calcium-dependent manner, with the exception of
Slp2-a that was unaffected by calcium.
Our functional studies using knockout mice for Slp1 and
Slp2-a revealed normal levels of CTL killing of target cells,
suggesting that loss of either Slp1 or Slp2-a alone is
insufficient to impair granule secretion from CTL. We
therefore used a dominant-negative construct consisting
of the SHD from Slp2-a fused to pmaxGFP expressed in
CTL to ask whether killing was inhibited. We reasoned that
because the SHD of Slp1 and Slp2-a are 56% identical and
73% similar in their amino acid sequences, this SHD might
inhibit both. We cannot rule out that this construct also
inhibits other proteins that might bind Rab27a or other
proteins involved in secretion by a similar SHD. However,
to date, the SHD has only been identified in the Slps, and
we have only detected expression of Slp1 and Slp2-a in
CTL. It seems likely that there are other components to
this complex as the SHD only gives a partial reduction in
target cell killing, but which proteins these are remains to
be determined.
Materials and Methods
Anti-Slp2-a SHD immunoglobulin G production
Recombinant glutathione S-transferase-tagged human Slp2-a SHD (corres-
ponding to amino acids 1–99 of Slp2-a) was expressed in the DH5a
Escherichia coli strain, harvested, purified and concentrated using an
Amicon Ultra-15 centrifugal filter. Anti-Slp2-a SHD polyclonal serum was
generated by Cambridge Research Biosciences after immunization with
recombinant protein or generated as described in Imai et al. (37). Immuno-
globulin G (IgG) was purified using a Protein A–Sepharose column
(Pharmacia), and specificity was checked by Western blot and immuno-
fluorescence on transfected cells.
Cell culture
All murine CTLs were derived from C57BL/6 mice. Freshly isolated
spleens were homogenized through a 70-mm strainer (Falcon) with the
plunger from a 2-mL syringe. Splenocytes were washed once with
454 Traffic 2008; 9: 446–457
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(FCS) and cultured with an equal number of Balb/c splenocytes irradiated
with 3000 rad in IMDM, 10% FCS, 100 U/mL recombinant interleukin-2,
55 mM 2-mercaptoethanol and 2 mM glutamine. After 5–7 days, CTLs
were isolated over Histopaque (Sigma) and cultured for 2–5 days before
use for staining, transfection or further rounds of stimulation. RBL cells
were cultured in DMEM/10% FCS.
Cloning and sequencing
The messenger RNA was isolated from cell pellets using a Qiagen RNeasy
extraction kit. cDNA was generated using a Superscript II reverse
transcriptase–polymerase chain reaction kit (Invitrogen). cDNA encoding
murine Slp2-a was amplified by polymerase chain reaction (PCR) using
Phusion high-fidelity polymerase (Finnzymes) with 50 primer atg atc gac tta
agt ttc ctg aca gag gag and 30 primer tca ctt gga aag ctt ggc aat cag aag cat.
cDNA encoding human Slp2-a was amplified by PCR using Pfu polymerase
(Stratagene) with 50 primer atc acc gcg ggc atg att gac tta agc ttc ctg act and
30 primer aata ccc ggg tca ttt gga aat ctt ggc aat caa. These Slp2-a cDNAs
were sequenced with overlapping primers to confirm sequence. A full-size
fragment of murine Slp2-a fragment with SalI and XmaI sites was
generated by PCR with 50 primer gatc gtc gac atg atc gac tta agt ttc ctg
aca gag and 30 primer gatc ccc ggg tca ctt gga aag ctt ggc aat cag aag, cut
with the respective restriction enzymes and cloned into the pmaxFP-Green-
C or -N vector (Amaxa). The dominant-negative murine Slp2-a construct
(corresponding to amino acids 1–99) was generated by PCR with 50 primer
gcg aat tct atg atc gac tta agt ttc ctg aca g and 30 primer gac tgg atc cct cat
tgc tgt gtc ctt att ctg ctc and cloned into the pmaxFP-Green-N vector
(Amaxa) at the BamHI and EcoRI restriction sites. All constructs were
confirmed by ABI sequencing before use.
Lysates and Western blotting for Slp2-a
Cell pellets were washed once with PBS and lysed at 1   10
7 cells/mL in
1% sodium dodecyl sulphate (SDS) containing complete protease inhibitor
(Boehringer) by repeated passing through a 19G needle. The supernatant
was centrifuged at 16 000   g for 10 min at 48C to remove nuclei and
membranes. Lysates were mixed with SDS loading buffer and heated to
958C for 5 min prior to separation on a 7.5% SDS–PAGE. Proteins were
transferred to a nitrocellulose membrane (Hybond; GE Healthcare) and
blocked with PBS, 5% milk, 0.2% Tween-20 for 1 h at room temperature.
Anti-Slp2-a SHD antibody was added in blocking buffer for at least 1 h,
followed by three washes with PBS and 0.2% Tween-20. Horseradish
peroxidase (HRP)-conjugated secondary antibody was incubated for 45 min
in PBS, 5% milk, 0.2% Tween-20 and washed three times as above before
development using Pierce Super Signal chemiluminescent reagent and
Kodak Biomax MR film.
Rab27a interactions
Mouse CTLs (2.5   10
7 cells) were homogenized in a buffer containing
50 mM HEPES–KOH, pH 7.2, 150 mM NaCl, 1 mM MgCl2, 0.5 mM GTPgS
and protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 mM
leupeptin and 10 mM pepstatin A) in a glass–Teflon Potter homogenizer
by 10 strokes at 1000 r.p.m., and the proteins were solubilized with 1%
Triton-X-100 at 48C for 1 h. After removing the insoluble material by
centrifugation at 17 400   g for 10 min, the supernatant was incubated
overnight with a 30 mL volume of protein A–Sepharose beads (Amersham
Biosciences) without a primary antibody for preabsorption. The supernatant
was then incubated with anti-Slp1-C2B IgG (15), anti-Slp2-a-C2B IgG (37) or
control anti-Slac2-c IgG (37) (10 mg/mL) for 1 h at 48C followed by
incubation with protein A–Sepharose beads for 1 h at 48C. After washing
the beads three times with 50 mM HEPES–KOH, pH 7.2, 150 mM NaCl and
0.2% Triton-X-100, the proteins bound to the beads were analyzed by 7.5–
12.5% gradient SDS–PAGE and then immunoblotted with anti-Rab27a
mouse monoclonal antibody (1/250 dilution; BD Transduction Laboratories),
anti-Slp1 SHD (4 mg/mL), anti-Slp2-a SHD (4 mg/mL) and anti-Slac2-c rabbit
polyclonal antibodies (4 mg/mL). SDS–PAGE and the immunoblot analysis
were performed as described previously (37). Immunoreactive bands were
visualized by enhanced chemiluminescence (Amersham Biosciences).
Digestion of Slp2-a by proteases
Recombinant T7-tagged Slp1-5 proteins were expressed in COS-7 cells and
purified with the anti-T7 tag antibody-conjugated agarose (Novagen) as
described previously (38), but all procedures were performed in the
absence of any protease inhibitors.Purified recombinant T7-Slp1–5 proteins
were incubated at 258C for 30 min with 100 ng/mL of trypsin. Digested
proteins were then analyzed by 12.5% SDS–PAGE followed by immuno-
blotting with HRP-conjugated anti-T7 tag antibody as described previously
(38). The immortalized melanocyte cell line melan-a (generous gift of
Dorothy C. Bennett) was cultured as described previously (39). Melan-a
cells (one 10-cm dish at confluence) were homogenized in 500 mLo fa
buffer (50 mM HEPES–KOH, pH 7.2, 1 mM MgCl2 and 150 mM NaCl) with-
out any protease inhibitors in a glass–Teflon Potter homogenizer with 10
strokes at 1000 r.p.m., and proteins were solubilized with 1% Triton-X-100
at 48C for 1 h. After removing the insoluble material by centrifugation
at 15 000 r.p.m. for 10 min, cell lysates were incubated at 308Cf o r1h
with either 2 mM EGTA or 750 mM Ca
2þ in the presence or absence of
calpain inhibitors (10 mM calpastatin peptide or 10 mM calpain inhibitor III;
Calbiochem-Novachem Corp.). Reactions were terminated by adding SDS
sample buffer and boiling for 3 min. Protein expression levels of Slp2-a
and actin were analyzed by immunoblotting with specific antibodies as
described previously (18).
Confocal microscopy
CTLs were plated in serum-free medium onto glass slides for 15 min before
complete media containing sera were added for a further 15 minutes. For
conjugate formation, CTLs were mixed with equal numbers of P815 target
cells before plating onto glass multi-well slides (Hendley). All cells were
washed in serum-free RPMI in order to adhere them to glass for 15 min
before adding back complete media containing serum. Cells were fixed
with ice-cold methanol for 5 min, washed extensively with 1% BSA/PBS,
followed by PBS, before mounting with PBS, and 90% glycerol containing
1,4, diazabicyclo(2,2,2)octane (DABCO). When counterstained with anti-
bodies, cells were stained for 1 h at room temperature with primary
antibody, washed extensively in 1% BSA/PBS and PBS prior to mounting.
Primary antibodies used in this study were rabbit anti-cathepsin D (Upstate
Biotechnology), -granzyme A, -Slp2-a SHD and rat anti-LAMP2, ABL93
(Developmental Studies Hybridoma Bank, Iowa). Secondary antibodies
conjugated to fluorescein isothiocyanate or Cy-3 were obtained from
Jackson Laboratories. Images were taken using a Zeiss Meta confocal
microscope and processed using Zeiss LSM image browser (www.zeiss.-
com) and ADOBE PHOTOSHOP.
Transfection and cytotoxicity assay
RBL cells were transfected by electroporation as previously described (40).
Three million human CD3 cells were stimulated with irradiated buffy coat
cells in RPMI, 5% human serum, 2% interleukin-2 for 7 days prior to
transfection with 10 mg Slp1 and Slp2-a DNA using the Amaxa nucleofec-
tor. About 2–4   10
7 murine CTLs after two, three or four rounds of
stimulation and 1–3 days post stimulation were nucleofected with 10 mgo f
DNA using an Amaxa nucleofector II, programme X-001 and the mouse
T cell nucleofection kit according to the manufacturer’s protocol. About
4   10
7 murine CTLs, stimulated four times after isolation from spleen,
were transfected with 10 mg Slp2-a constructs. The Slp2-a dominant-
negative construct consisted of DNA encoding the first 100 amino acids
of mouse Slp2-a fused to pmaxGFP at the carboxy terminus of Slp2-a. After
4.5 h, live cells were sorted to collect green cells (at fluorescence channel 1
(FL1) log >10
1). Sorted cells were then used immediately to perform
a killing assay using the Cytotox 96 assay (Promega) using P815 cells as
targets.
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